Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 18
2005 17
2006 7
2007 5
2008 6
2009 4
2010 7
2011 5
2012 5
2013 9
2014 3
2015 2
2016 2
2017 3
2018 5
2019 3
2020 2
2021 5
2022 5
2023 3
2024 1
2025 5
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

108 results

Results by year

Filters applied: . Clear all
Page 1
Defining proteoform-specific interactions for drug targeting in a native cell signalling environment.
Lutomski CA, Bennett JL, El-Baba TJ, Wu D, Hinkle JD, Burnap SA, Liko I, Mullen C, Syka JEP, Struwe WB, Robinson CV. Lutomski CA, et al. Nat Chem. 2025 Feb;17(2):204-214. doi: 10.1038/s41557-024-01711-w. Epub 2025 Jan 13. Nat Chem. 2025. PMID: 39806141 Free PMC article.
Given reports of undesirable side-effects involving vision, we characterized the off-target drug binding of two phosphodiesterase 5 inhibitors, vardenafil and sildenafil, to the retina rod phosphodiesterase 6 (PDE6). The results demonstrate differential off-target reactivi …
Given reports of undesirable side-effects involving vision, we characterized the off-target drug binding of two phosphodiesterase 5 inhibito …
Vardenafil treatment for erectile dysfunction.
Crowe SM, Streetman DS. Crowe SM, et al. Ann Pharmacother. 2004 Jan;38(1):77-85. doi: 10.1345/aph.1D019. Ann Pharmacother. 2004. PMID: 14742800 Review.
Only human studies were used to gather pharmacokinetic, drug interaction, efficacy, and safety data. DATA SYNTHESIS: Vardenafil is a potent and selective inhibitor of the phosphodiesterase 5 (PDE5) enzyme that has been shown to improve erectile function in several p …
Only human studies were used to gather pharmacokinetic, drug interaction, efficacy, and safety data. DATA SYNTHESIS: Vardenafil …
Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events.
Bischoff E. Bischoff E. Int J Impot Res. 2004 Jun;16 Suppl 1:S34-7. doi: 10.1038/sj.ijir.3901213. Int J Impot Res. 2004. PMID: 15224134 Review.
Vardenafil potently inhibits human phosphodiesterase 5 (PDE5) with an IC50 of 0.7 nM. Enhancement of nitric oxide (NO)-induced erections in rabbits by 0.1 mg/kg vardenafil is limited by its pharmacokinetic properties (Tmax=1 h; T1/2=1.2 h), although erectile effects …
Vardenafil potently inhibits human phosphodiesterase 5 (PDE5) with an IC50 of 0.7 nM. Enhancement of nitric oxide (NO)-induced erecti …
Interactions between grapefruit juice and cardiovascular drugs.
Bailey DG, Dresser GK. Bailey DG, et al. Am J Cardiovasc Drugs. 2004;4(5):281-97. doi: 10.2165/00129784-200404050-00002. Am J Cardiovasc Drugs. 2004. PMID: 15449971 Review.
In contrast, the therapeutic effect of the angiotensin II type 1 receptor antagonist losartan may be reduced by grapefruit juice. Grapefruit juice interacting with the antidiabetic agent repaglinide may cause hypoglycemia, and interaction with the appetite suppressa …
In contrast, the therapeutic effect of the angiotensin II type 1 receptor antagonist losartan may be reduced by grapefruit juice. Grapefruit …
Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence.
Morales AM, Mirone V, Dean J, Costa P. Morales AM, et al. Clin Interv Aging. 2009;4:463-72. doi: 10.2147/cia.s3878. Epub 2009 Dec 29. Clin Interv Aging. 2009. PMID: 20054411 Free PMC article. Review.
Therefore, cardiovascular safety and potential drug interactions are two of the major concerns when using PDE-5 inhibitors in these patients. ...Importantly, the concomitant use of medication for these conditions is not associated with any noteworthy changes in the efficac …
Therefore, cardiovascular safety and potential drug interactions are two of the major concerns when using PDE-5 inhibitors in these p …
Effects of tadalafil on skeletal muscle tissue: exploring interactions and novel mechanisms of action.
Antinozzi C, Greco EA, Sgrò P, Dimauro I, Aversa A, DI Luigi L. Antinozzi C, et al. Minerva Endocrinol (Torino). 2023 Jun;48(2):222-229. doi: 10.23736/S2724-6507.21.03698-8. Epub 2022 Feb 4. Minerva Endocrinol (Torino). 2023. PMID: 35119252 Review.
Different drugs inhibiting PDE5 (PDE5i) exist, and the commercially available PDE5i are sildenafil, vardenafil, tadalafil, and avanafil. The PDE5i tadalafil may influence cellular physiology and endocrine-metabolic pathways in skeletal muscles and exerts its functions both …
Different drugs inhibiting PDE5 (PDE5i) exist, and the commercially available PDE5i are sildenafil, vardenafil, tadalafil, and avanaf …
Prostaglandins as a Topical Therapy for Erectile Dysfunction: A Comprehensive Review.
Hamzehnejadi M, Tavakoli MR, Homayouni F, Jahani Z, Rezaei M, Langarizadeh MA, Forootanfar H. Hamzehnejadi M, et al. Sex Med Rev. 2022 Oct;10(4):764-781. doi: 10.1016/j.sxmr.2022.06.004. Sex Med Rev. 2022. PMID: 36210096 Review.
OBJECTIVES: Unfortunately, due to various interactions, contraindications, and side effects, systemic therapies such as phosphodiesterase-5 inhibitors (including sildenafil, tadalafil, vardenafil, avanafil, etc.) are not welcomed in many patients. ...
OBJECTIVES: Unfortunately, due to various interactions, contraindications, and side effects, systemic therapies such as phosphodieste …
New drugs of 2003.
Hussar DA. Hussar DA. J Am Pharm Assoc (2003). 2004 Mar-Apr;44(2):168-206; quiz 207-10. doi: 10.1331/154434504773062627. J Am Pharm Assoc (2003). 2004. PMID: 15098851 Review.
DATA SYNTHESIS: The 28 new therapeutic agents marketed in the United States during 2003 are reviewed in this article: adalimumab, agalsidase beta, alefacept, alfuzosin hydrochloride, aprepitant, atazanavir sulfate, atomoxetine hydrochloride, bortezomib, daptomycin, efalizumab, el …
DATA SYNTHESIS: The 28 new therapeutic agents marketed in the United States during 2003 are reviewed in this article: adalimumab, agalsidase …
Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension.
Gur S, Kadowitz PJ, Gokce A, Sikka SC, Lokman U, Hellstrom WJ. Gur S, et al. Curr Drug Metab. 2013 Feb;14(2):265-9. Curr Drug Metab. 2013. PMID: 23140258 Review.
Phosphodiesterase-5 inhibitors (PDE5i, sildenafil, vardenafil, tadalafil and avanafil) are a first-line medical therapy for erectile dysfunction (ED). ...Current literature reports a number of interactions between PDE5i and other agents and further studies are neede …
Phosphodiesterase-5 inhibitors (PDE5i, sildenafil, vardenafil, tadalafil and avanafil) are a first-line medical therapy for erectile …
108 results